Pharmacokinetic-pharmacodynamic evaluation of ceftazidime continuous infusion vs intermittent bolus injection in septicaemic melioidosis (Q36053937)

11 August 2017

Pharmacokinetic-pharmacodynamic evaluation of ceftazidime continuous infusion vs intermittent bolus injection in septicaemic melioidosis. (English)

1 reference

11 August 2017

0 references

1 reference

1 reference

1 reference

8

N J White

1 reference

11 August 2017

B J Angus

1

1 reference

11 August 2017

M D Smith

2

1 reference

11 August 2017

Y Suputtamongkol

3

1 reference

11 August 2017

H Mattie

4

1 reference

11 August 2017

A L Walsh

5

1 reference

11 August 2017

V Wuthiekanun

6

1 reference

11 August 2017

W Chaowagul

7

1 reference

11 August 2017

language of work or name

English

0 references

publication date

1 August 2000

1 reference

British Journal of Clinical Pharmacology

11 August 2017

1 reference

11 August 2017

50

1 reference

11 August 2017

184-191

1 reference

11 August 2017

2

1 reference

In vitro pharmacodynamics of ceftazidime against Pseudomonas aeruginosa isolates from cystic fibrosis patients

11 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014399

Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infections

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014399

Prognostic significance of quantitative bacteremia in septicemic melioidosis

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014399

A prospective comparison of co-amoxiclav and the combination of chloramphenicol, doxycycline, and co-trimoxazole for the oral maintenance treatment of melioidosis

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014399

Multiple-dose pharmacokinetics of amikacin and ceftazidime in critically ill patients with septic multiple-organ failure during intermittent hemofiltration

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014399

Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014399

Ceftazidime vs. amoxicillin/clavulanate in the treatment of severe melioidosis

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014399

The epidemiology of melioidosis in Ubon Ratchatani, northeast Thailand

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014399

Beta-lactam antibiotics: is continuous infusion the preferred method of administration?

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014399

Susceptibility of Pseudomonas pseudomallei to some newer beta-lactam antibiotics and antibiotic combinations using time-kill studies

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014399

Pharmacokinetics of ceftazidime in normal and uremic subjects

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014399

Pharmacokinetics of ceftazidime in male and female volunteers

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014399

Antimicrobial activity, pharmacokinetics, therapeutic indications and adverse reactions of ceftazidime

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014399

Ceftazidime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014399

Effect of protein binding on serum bactericidal activities of ceftazidime and cefoperazone in healthy volunteers

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014399

Role of pharmacokinetics in the outcome of infections

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014399

Prediction of creatinine clearance from plasma creatinine: comparison of five formulae

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014399

Melioidosis: a major cause of community-acquired septicemia in northeastern Thailand

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014399

The antimicrobial susceptibility of Pseudomonas pseudomallei. Emergence of resistance in vitro and during treatment

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014399

Determinants of efficacy and toxicity of aminoglycosides

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014399

Advancing age and acute infection influence the kinetics of ceftazidime

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014399

Halving of mortality of severe melioidosis by ceftazidime

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014399

Identification of Pseudomonas pseudomallei in clinical practice: use of simple screening tests and API 20NE.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014399

The use of selective media for the isolation of Pseudomonas pseudomallei in clinical practice

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014399

Once-daily aminoglycoside therapy

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014399

Prediction of creatinine clearance from serum creatinine

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014399

Ceftazidime in the treatment of Pseudomonas infections in intensive-care patients.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014399

Pharmacokinetics of ceftazidime and netilmicin in patients with sepsis

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014399

Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014399

Pharmacokinetics of antibiotics in critically ill patients.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014399

Pharmacokinetics of ceftazidime in patients with liver cirrhosis and ascites

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014399

Intermittent bolus dosing of ceftazidime in critically ill patients.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014399

Determination of ceftazidime in biological fluids by using high-pressure liquid chromatography

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014399

Continuous infusion ceftazidime in intensive care: a randomized controlled trial

23 September 2018

1 reference

12 December 2020

The pharmacodynamics of beta-lactams

1 reference

12 December 2020

Safety and pharmacokinetics of ceftazidime in patients with chronic hepatic dysfunction

1 reference

12 December 2020

Prediction by APACHE score

1 reference

12 December 2020

Dosage adjustment for ceftazidime in patients with impaired renal function

1 reference

12 December 2020

Single- and multiple-dose pharmacokinetics of ceftazidime in infected patients with varying degrees of renal function

1 reference

12 December 2020

Study of the influence of protein binding on serum bactericidal titres and killing rates in volunteers receiving ceftazidime, cefotaxime and ceftriaxone

1 reference

12 December 2020

Influence of the Mode of Intravenous Administration on the Penetration of Ceftazidime into Tissues and Pleural Exudate of Rats

1 reference

12 December 2020

Continuous infusion of ceftazidime in cystic fibrosis patients during home treatment: clinical outcome, microbiology and pharmacokinetics

1 reference

12 December 2020

Continuous infusion of ceftazidime with an elastomeric infusion device

1 reference

12 December 2020

10.1111/J.1365-2125.2000.00179.X

Identifiers

DOI

1 reference

11 August 2017

1 reference

11 August 2017

1 reference